4D Molecular Therapeutics FDMT Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's deferred revenue?
- 4D Molecular Therapeutics (FDMT) reported deferred revenue of $360K in Q1 2026.
- How has 4D Molecular Therapeutics's deferred revenue changed year-over-year?
- 4D Molecular Therapeutics's deferred revenue decreased by 58.4% year-over-year, from $866K to $360K.
- What is the long-term trend for 4D Molecular Therapeutics's deferred revenue?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's deferred revenue has grown at a -44.1% compound annual growth rate (CAGR), from $6.59M to $360K.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.